Table 3 EMA approved biosimilars (European Medicines Agency 2016)
Date of biosimilar EMA approval | Biosimilar product | Original product | Active substance |
|---|---|---|---|
12 April 2006 | Omnitrope | Genotropin | Somatropin |
28 August 2007 | Abseamed | Epogen/Eprex | Epoetin alfa |
28 August 2007 | Binocrit | Epogen/Eprex | Epoetin alfa |
28 August 2007 | Epoetin Alfa Hexal | Epogen/Eprex | Epoetin alfa |
18 December 2007 | Silapo | Epogen/Eprex | Epoetin zeta |
18 December 2007 | Retacrit | Epogen/Eprex | Epoetin zeta |
15 September 2008 | Biograstim | Neupogen | Filgrastim |
15 September 2008 | Ratiograstim | Neupogen | Filgrastim |
15 September 2008 | Tevagrastim | Neupogen | Filgrastim |
06 February 2009 | Filgrastim Hexal | Neupogen | Filgrastim |
06 February 2009 | Zarzio | Neupogen | Filgrastim |
08 June 2010 | Nivestim | Neupogen | Filgrastim |
10 September 2013 | Inflectra | Remicade | Infliximab |
27 September 2013 | Ovaleap | Gonal-f | Follitropin alfa |
10 October 2013 | Remsima | Remicade | Infliximab |
18 October 2013 | Grastofil | Neupogen | Filgrastim |
27 March 2014 | Bemfola | Gonal-f | Follitropin alfa |
09 September 2014 | Abasaglar (previously Abasria) | Lantus | Insulin glargine |
18 September 2014 | Accofil | Neupogen | Filgrastim |
14 January 2016 | Benepali | Enbrel | Etanercept |
26 May 2016 | Flixabi | Remicade | Infliximab |